Testosterone MD-Lotion

DRUG5 trials

Sponsors

Eli Lilly and Company, Acrux DDS Pty Ltd

Conditions

HypergonadismHypogonadism

Phase 1

To Determine the Effects of Deodorant, Antiperspirant and Washing on the Pharmacokinetics of 2% Testosterone MD Lotion

CompletedNCT00857168

Acrux DDS Pty LtdHypogonadism

Start: 2009-01-31End: 2009-04-30Target: 36Updated: 2009-10-14

Testosterone MD-Lotion Residual Washing Study

CompletedNCT00996151

Acrux DDS Pty LtdHypergonadism

Start: 2009-12-31End: 2010-02-28Updated: 2010-03-02

Phase 2

A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations

CompletedNCT00857961

Eli Lilly and CompanyHypogonadism

Start: 2007-10-31End: 2008-01-31Updated: 2011-01-07

Phase 3

A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations

CompletedNCT00702650

Eli Lilly and CompanyHypogonadism

Start: 2008-06-30End: 2009-07-31Updated: 2011-07-25

A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations

CompletedNCT00857454

Eli Lilly and CompanyHypogonadism

Start: 2008-10-31End: 2009-08-31Updated: 2011-01-05

Related Papers

Utility of a single serum testosterone measurement to determine response to topical testosterone replacement in hypogonadal men.

2015-12-151 citations